IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Gemcitabine based combination regimens for treatment of refractory advanced breast cancer
Che Li; Di Li-jun; Song Guo-hong; Jia Jun; Yu Jing; Wang Xiao-li; Zhu Yu-lin; Jiang Han-fang; Liang Xu
关键词advanced breast cancer gemcitabine salvage chemotherapy anthracycline taxane
刊名CHINESE JOURNAL OF CANCER RESEARCH
2008-09-01
DOI10.1007/s11670-008-0194-x
20期:3页:194-201
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PHASE-II TRIAL ; COLONY-STIMULATING FACTOR ; ADMINISTERED EVERY ; 2ND-LINE TREATMENT ; DOCETAXEL ; VINORELBINE ; CHEMOTHERAPY
英文摘要

Objective: Anthracycline and taxane are the standard agents in combined chemotherapy of advanced breast cancer. However, when these agents based chemotherapy is failure, the selection of salvage regimen is still of problem. Gemcitabine, an active agent in both lung cancer and pancreas cancer, is demonstrated effective in breast caner. But there have been relatively less data of gemcitabine in anthracycline and/or taxane-resistant breast cancer. Therefore we employe this study to explore the efficacy and safety of gemcitabine based combination regimen in this population. Methods: From May 2002 to March 2006, 28 patients with measurable lesion of advanced metastatic breast cancer who were resistant to prior anthracycline and taxane based chemotherapy were enrolled. Patients were treated with gemcitabine based combination chemotherapy with a median cycles of 3 (range 2-6). Results: The overall response rate was 28.6% (8/28), with 1 CR (Complete response 3.5%) and 7 PRs (Partial response 25%). Stable disease was seen in 8 patients (28.6%) while disease progressed in 12 patiens (42.8%). The median time to progression was 4.5 m (range, 2-23 m). The main toxicity included bone marrow depression, alopecia, mucositis and peripheral neurotoxicity. The grade 3 to 4 clinical adverse effect was leukopenia in 5 cases (17.9%) and thrombocytopenia in 8 cases (30%). Conclusion: Gemcitabine based combination regimens is feasible in anthracycline and taxane-resistant advanced breast cancer. The clinical response and TTP is acceptable with limited toxicity pattern.

语种英语
WOS记录号WOS:000259368400008
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58252
专题北京大学临床肿瘤学院
北京大学公共卫生学院_妇女与儿童青少年卫生学系
北京大学临床肿瘤学院_乳腺肿瘤内科
北京大学临床肿瘤学院_移植与免疫治疗病区
作者单位Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Breast Canc Internal Oncol, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Che Li,Di Li-jun,Song Guo-hong,et al. Gemcitabine based combination regimens for treatment of refractory advanced breast cancer[J]. CHINESE JOURNAL OF CANCER RESEARCH,2008,20(3):194-201.
APA Che Li.,Di Li-jun.,Song Guo-hong.,Jia Jun.,Yu Jing.,...&Liang Xu.(2008).Gemcitabine based combination regimens for treatment of refractory advanced breast cancer.CHINESE JOURNAL OF CANCER RESEARCH,20(3),194-201.
MLA Che Li,et al."Gemcitabine based combination regimens for treatment of refractory advanced breast cancer".CHINESE JOURNAL OF CANCER RESEARCH 20.3(2008):194-201.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Che Li]的文章
[Di Li-jun]的文章
[Song Guo-hong]的文章
百度学术
百度学术中相似的文章
[Che Li]的文章
[Di Li-jun]的文章
[Song Guo-hong]的文章
必应学术
必应学术中相似的文章
[Che Li]的文章
[Di Li-jun]的文章
[Song Guo-hong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。